Methods and materials for treating cancer
AssigneeMayo Foundation for Medical Education and Research
InventorsRory L. Smoot, Tushar C. Patel, Sumera I. Ilyas
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials for treating cancer. For example, this document provides vesicles (e.g., nanovesicles) designed to deliver one or more (e.g., one, two, three, or more) inhibitors to a cancer cell within a mammal (e.g., a human) having cancer to treat the mammal's cancer.
Claims24
A vesicle comprising a first inhibitor located within said vesicle, a second inhibitor located within said vesicle, a third inhibitor located within said vesicle, and a targeting moiety located on a surface of said vesicle, wherein said first inhibitor inhibits expression or activity of a first polypeptide, wherein said second inhibitor inhibits expression or activity of a second polypeptide, wherein said third inhibitor inhibits expression or activity of a third polypeptide, wherein said first polypeptide, said second polypeptide, and said third polypeptide are selected from the group consisting of a YAP polypeptide, a TAZ polypeptide, a LCK polypeptide, and a TRAIL polypeptide, wherein said targeting moiety binds to a molecule present on the surface of a cancer cell, and wherein said vesicle has a longest diameter of 5 nm to 500 nm.
2-11. (canceled)
(canceled)
20-25. (canceled)
A vesicle comprising an inhibitor located within said vesicle and a targeting moiety located on a surface of said vesicle, wherein said inhibitor inhibits expression or activity of a LCK polypeptide or a TRAIL polypeptide, wherein said targeting moiety binds to a molecule present on the surface of a cancer cell, and wherein said vesicle has a longest diameter of 5 nm to 500 nm.
33-38. (canceled)
A method for treating cancer, wherein said method comprises administering a composition comprising a vesicle to a mammal having cancer, wherein the number of cancer cells within said mammal is reduced following said administering of said composition, wherein said vesicle comprises a first inhibitor located within said vesicle, a second inhibitor located within said vesicle, a third inhibitor located within said vesicle, and a targeting moiety located on a surface of said vesicle, wherein said first inhibitor inhibits expression or activity of a first polypeptide, wherein said second inhibitor inhibits expression or activity of a second polypeptide, wherein said third inhibitor inhibits expression or activity of a third polypeptide, wherein said first polypeptide, said second polypeptide, and said third polypeptide are selected from the group consisting of a YAP polypeptide, a TAZ polypeptide, a LCK polypeptide, and a TRAIL polypeptide, wherein said targeting moiety binds to a molecule present on the surface of a cancer cell, and wherein said vesicle has a longest diameter of 5 nm to 500 nm.
43-46. (canceled)
Dependencies are inferred from the claim text.